Full-Time

Decision Analytics Consultant

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Madrid, Spain

In Person

Category
Business & Strategy (1)
Required Skills
Power BI
Mixpanel
Usability Testing/Engineering
Figma
SQL
A/B Testing
Tableau
JIRA
Hotjar
Confluence
Data Governance
Excel/Numbers/Sheets
Google Analytics
Requirements
  • Experience: 5+ years of experience in Business Analysis or Consultancy, with at least 3+ years within the Life Sciences/Pharma industry.
  • Education: Bachelor’s degree in Information Systems / Information Technology, Computer Science, Business Administration (with a focus on IT, Analytics, or Operations), Human-Computer Interaction (HCI) or UX-related discipline, Data Analytics / Data Science.
  • Analytical Mastery: SQL, BI tools (Tableau/Power BI), UX analytics platforms (Google Analytics, Mixpanel), and collaboration tools (Jira, Confluence). Familiarity with UX design tools (Figma)
  • Strategic Thinking: Demonstrated experience translating requirements into implementation plans that align with global business objectives.
  • Communication: Bilingual proficiency (English and Spanish) with exceptional ability to influence and facilitate workshops at all levels of the organization.
  • Mindset: Proactive, creative problem-solver with a strong dedication to mentoring and organizational development.
Responsibilities
  • Strategic Advisory & Leadership: Independently manage end-to-end BA workstreams. You will act as a consultant to cross-functional teams, shaping stakeholder perspectives and aligning project goals with long-term solution roadmaps.
  • Data-Driven Decision Making: Ability to gather, analyze, and interpret complex datasets (quantitative and qualitative) to inform product and UX decisions; Experience translating user behavior, metrics, and feedback into actionable insight; Proficiency in tools such as SQL, Excel, or Tableau
  • Solution Design & Product Development: Translate complex business requirements into strategic implementation plans. You will design data products (datasets, KPI frameworks) and evaluate vendor solutions to ensure they meet our technical and business standards.
  • User Behavior & Experience Analysis: Strong capability to analyze user journeys, pain points, and interaction patterns; Experience with usability testing, A/B testing, and heuristic evaluations; Familiarity with UX research tools such as Google Analytics, Hotjar, or Mixpanel
  • Requirements Elicitation & Problem Structuring: Expertise in breaking down ambiguous business problems into structured requirements and hypotheses; Ability to synthesize stakeholder needs, technical constraints, and user expectations into clear functional and non-functional requirements; Skilled in creating user stories, acceptance criteria, and process flows
  • Process Excellence & Mentorship: As a senior member of our Community of Practice, you will mentor junior and intermediate BAs, proactively shaping our methodologies and driving continuous improvement in our operational workflows.
  • Technical Integrity: Drive the analysis and ensure comprehensive requirements traceability, maintaining a focus on data governance and change management
Desired Qualifications
  • Master’s degree (or equivalent experience) in MBA (Information Systems or Product Management focus), Human-Computer Interaction (HCI),Data Analytics / Business Analytics is highly desirable

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Your Connections

People at Roche who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VENTANA PTEN RxDx creates a new prostate cancer companion-diagnostic revenue stream.
  • PathAI acquisition expands AI-driven diagnostics and global digital pathology workflow integration.
  • Nurix collaboration extends Roche into BTK degraders across hematology and immunology.

What critics are saying

  • Swiss franc strength continues depressing reported earnings from Roche’s Swiss cost base.
  • Upcoming patent expirations threaten legacy pharmaceutical revenue before new launches mature.
  • Obesity competition from Novo Nordisk and Eli Lilly leaves CT-388 behind.

What makes Roche unique

  • Roche unites pharmaceuticals, diagnostics, and digital pathology across healthcare workflows.
  • Founded in Basel in 1896, Roche built scale through branded medicines.
  • Genentech acquisition made Roche the world’s largest biotechnology company.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.